Citizens JMP analyst Jason Butler reiterated a Market Outperform rating and $91.00 price target on Halozyme Therapeutics (NASDAQ: HALO).The analyst ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE